![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BSP Receives FDA Approval for New ECG Technology
BSP Receives FDA Approval for New ECG Technology
March 30, 2005
BSP Biological Signal Processing announced that it
has received FDA approval for the marketing and sale of its HyperQ System. BSP,
a company in the field of high-frequency electrocardiogram (HF ECG), has developed
superior ECG technology, with breakthrough diagnostic value for detecting and
monitoring ischemic heart diseases — the leading cause of death in the developed
world. BSP's HyperQ System is a PC-based stress ECG device that records, analyses
and displays both conventional stress ECG and HF ECG for detection of myocardial
ischemia.
PR
Newswire
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct